Juvenile dermatomyositis: clinical profile and disease course in 25 patients.

A retrospective analysis of 25 Arab patients with juvenile dermatomyositis (JDMS) was conducted between 1988 and 1996. The mean age at disease onset was 8.25 years (range 1.

Methotrexate therapy in systemic-onset juvenile rheumatoid arthritis in Saudi Arabia: a retrospective analysis.

Eighteen patients (nine girls, nine boys) with systemic onset juvenile rheumatoid arthritis (SO-JRA) treated with methotrexate (MTX) for a mean period of 18 months (range 6-41 months) were analysed to evaluate the safety and efficacy of MTX in this disease subtype. The MTX dose ranged from 2.5 to 15 mg/week with a mean cumulative dose of 684.

Juvenile Behçet's disease in Arab children.

Behçet's disease is a chronic, relapsing, multisystem disease characterized by the clinical triad of genital ulcers, oral ulcers and ocular involvement. Twelve Saudi children are presented, all of whom satisfied the international criteria for the classification of Behçet's disease and whose initial manifestations appeared at or before the age of 16 years. The male-to-female ratio was 1.

Enhanced interleukin 8 secretion in circulation of patients with Behçet's disease.

Objective: The pathogenesis of Behçet's disease (BD) has not yet been determined. Several hypotheses have been postulated and cytokines that control growth proliferation and hematopoiesis of progenitor cells play a role in relation to immune response and inflammatory dysfunction. We investigated whether cytokines play a role in pathogenesis of BD.

Behçet's disease in Saudi Arabia.

Objective: To study the presentation of Behçet's disease (BD) in the Saudi population and to determine any differences in clinical manifestation and prognosis between men and women.

Methods: One hundred nineteen patients with BD attending the King Faisal Specialist Hospital and Research Centre (KFSH & RC) and the King Khalid University Hospital (KKUH) between 1979 and 1992 were studied.

Results: The male to female ratio was 3.